Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...
11h
Fintel on MSNOppenheimer Upgrades Nektar Therapeutics (NKTR)Fintel reports that on March 14, 2025, Oppenheimer upgraded their outlook for Nektar Therapeutics (NasdaqCM:NKTR) from ...
Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...
Shuttle Pharmaceuticals SHPH stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. AirSculpt Technologies AIRS shares decreased by 16.33 ...
Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December ...
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...
Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...
Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...
The San Francisco-based company said it had net income of 3 cents per share. Earnings, adjusted for non-recurring costs, came to 15 cents per share. The results topped Wall Street expectations. The ...
Shares of Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) have earned a consensus rating of “Buy” from the six analysts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results